IgG subclasses in human immune response to wild and attenuated (vaccine) Junin virus infection
- PMID: 12526057
- DOI: 10.1002/jmv.10308
IgG subclasses in human immune response to wild and attenuated (vaccine) Junin virus infection
Abstract
Different proportions of IgG subclasses have previously been reported to distinguish the immune response elicited by primary and recurrent viral infections, as well as viral vaccines. The goal of this study was to study the IgG subclasses composition in the immune response of patients with Argentine hemorrhagic fever, and vaccinees with Candid #1 strain of Junin virus. Twenty-four individuals inoculated with Candid #1 vaccine and 67 patients with Argentine hemorrhagic fever were studied. Blood samples were drawn at 30, 60, and/or 180 days post-inoculation with Candid #1 and 30, 60, and 90 days after clinical onset of the disease. Specific anti-Junin virus IgG subclasses were titrated with specific human monoclonal antibody fluorescence isothiocyanate conjugate (FITC) by immunofluorescent assay (IFA). IgG(1) anti-Junin virus was found in every subject studied and IgG(3) was also detected in some patients with a severe form of Argentine hemorrhagic fever. IgG(2) and IgG(4) were not detected in any serum sample studied. The mean titer of specific IgG(1) in vaccinees was significantly lower than in patients with Argentine hemorrhagic fever (P < 0.05), but no difference was found between mild and severe cases of the disease (P > 0.05). The results of this study demonstrated a central role of IgG(1) in human recovery from infection with every strain of Junin virus, an observation stressed by the immune response to Candid #1 vaccine, which resulted in no difference in IgG subclasses composition from that found in mild cases of Argentine hemorrhagic fever.
Copyright 2003 Wiley-Liss, Inc.
Similar articles
-
[Preclinical assay of candid #1 vaccine against Argentine Hemorrhagic Fever made in Argentina].Medicina (B Aires). 2005;65(4):329-32. Medicina (B Aires). 2005. PMID: 16193711 Spanish.
-
[Candid#1 vaccine against Argentine hemorrhagic fever produced in Argentina. Immunogenicity and safety].Medicina (B Aires). 2010;70(3):215-22. Medicina (B Aires). 2010. PMID: 20529769 Clinical Trial. Spanish.
-
[Phenotypic markers of attenuation in Junin virus strains recently isolated from individuals vaccinated with Junin Candid#1 strain].Medicina (B Aires). 2013;73(4):303-9. Medicina (B Aires). 2013. PMID: 23924527 Spanish.
-
Toward a vaccine against Argentine hemorrhagic fever.Bull Pan Am Health Organ. 1991;25(2):118-26. Bull Pan Am Health Organ. 1991. PMID: 1654168 Review.
-
Junín virus pathogenesis and virus replication.Viruses. 2012 Oct 19;4(10):2317-39. doi: 10.3390/v4102317. Viruses. 2012. PMID: 23202466 Free PMC article. Review.
Cited by
-
Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses.Nat Commun. 2018 May 14;9(1):1884. doi: 10.1038/s41467-018-04271-z. Nat Commun. 2018. PMID: 29760382 Free PMC article.
-
Immunization with GP1 but Not Core-like Particles Displaying Isolated Receptor-Binding Epitopes Elicits Virus-Neutralizing Antibodies against Junín Virus.Vaccines (Basel). 2022 Jan 22;10(2):173. doi: 10.3390/vaccines10020173. Vaccines (Basel). 2022. PMID: 35214632 Free PMC article.
-
The third inactivated vaccine booster dramatically enhanced SARS-CoV-2 antibody responses and did not influence the profile of prothrombotic antibody.J Med Virol. 2023 Jan;95(1):e28356. doi: 10.1002/jmv.28356. J Med Virol. 2023. PMID: 36443279 Free PMC article.
-
Viral zoonoses in Europe.FEMS Microbiol Rev. 2005 Nov;29(5):1051-77. doi: 10.1016/j.femsre.2005.04.012. Epub 2005 Jun 29. FEMS Microbiol Rev. 2005. PMID: 16024128 Free PMC article. Review.
-
Differential Antibody-Based Immune Response against Isolated GP1 Receptor-Binding Domains from Lassa and Junín Viruses.J Virol. 2019 Apr 3;93(8):e00090-19. doi: 10.1128/JVI.00090-19. Print 2019 Apr 15. J Virol. 2019. PMID: 30728269 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources